Gyre Therapeutics Inc.

Contributing Author

Recent Articles by Gyre Therapeutics Inc.

Jun-10	Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China GYRE GlobeNewswire
May-29	Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares GYRE GlobeNewswire
May-22	Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock GYRE GlobeNewswire
May-22	Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock GYRE GlobeNewswire
May-22	Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China GYRE GlobeNewswire
May-09	Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GYRE GlobeNewswire